Skip to main content
SpringerLink
Log in

Angiotensin II Receptor Blockers

  • Chapter
  • First Online:
Adverse Cutaneous Drug Reactions to Cardiovascular Drugs

  • 941 Accesses

Abstract

The angiotensin II receptor blockers (ARBs) inhibit the activity of angiotensin II at the angiotensin II receptor level (AT-1, AT-2 receptors). Losartan potassium is the prototype of the ARBs. Others are candesartan, irbesartan, valsartan, telmisartan, olmesartan, eprosartan, and azilsartan.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyrmizakis DE, Papadakis CE, Liolios AD, Karatzanis AD, Malandrakis S, Skoulakis CE, et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Arch Otolaryngol Head Neck Surg. 2004;130:1416–9.

    Article  PubMed  Google Scholar 

  2. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med. 1998;158:2063–5.

    Article  PubMed  Google Scholar 

  3. Nykamp D, Winter EE. Olmesartan medoxomil-induced angioedema. Ann Pharmacother. 2007;41:518–20.

    Article  CAS  PubMed  Google Scholar 

  4. Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother. 2003;37:1024–7.

    Article  PubMed  Google Scholar 

  5. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002;22:1173–5.

    Article  PubMed  Google Scholar 

  6. Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy. 1998;18:866–8.

    CAS  PubMed  Google Scholar 

  7. Borazan A, Ustün H, Yilmaz A. Angioedema induced by angiotensin II blocker telmisartan. Allergy. 2003;58:454.

    Article  CAS  PubMed  Google Scholar 

  8. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope. 2001;111:1729–31.

    Article  CAS  PubMed  Google Scholar 

  9. Nielsen EW. Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values. J Intern Med. 2005;258:385–7.

    Article  CAS  PubMed  Google Scholar 

  10. Kazim SF, Shahid M. Losartan associated anaphylaxis and angioneurotic oedema. J Pak Med Assoc. 2010;60:685–6.

    PubMed  Google Scholar 

  11. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med. 2003;163:240–1.

    Article  PubMed  Google Scholar 

  12. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495–9.

    Article  PubMed  Google Scholar 

  13. MacLean JA, Hannaway PJ. Angioedema and AT1 receptor blockers: proceed with caution. Arch Intern Med. 2003;163:1488–9.

    Article  PubMed  Google Scholar 

  14. Rasmussen ER, Mey K, Bygum A. Angiotensin-converting enzyme inhibitor-induced angioedema – a dangerous new epidemic. Acta Derm Venereol. 2014;94:260–4. doi:10.2340/00015555-1760.

    Article  PubMed  Google Scholar 

  15. Bork K, Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med. 2004;116:644–5.

    Article  PubMed  Google Scholar 

  16. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213–7.

    Article  CAS  PubMed  Google Scholar 

  17. Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, Vinnakota R, et al. Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther. 2011;18:e78–80.

    Article  PubMed  Google Scholar 

  18. Kawamura A, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol. 2003;13:406–7.

    PubMed  Google Scholar 

  19. Marquart-Elbaz C, Grosshans E, Lipsker D, Lipsker D. Sartans, angiotensin II receptor antagonists, can induce psoriasis. Br J Dermatol. 2002;147:617–8.

    Article  CAS  PubMed  Google Scholar 

  20. AT1-receptor antagonists and psoriasis. http://www.lareb.nl/LarebCorporateWebsite/media/publicaties/kwb_2006_1_angio.pdf. Accessed 14 May 2014.

  21. Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35:447–50.

    Article  CAS  PubMed  Google Scholar 

  22. Touraud JP, Collet E, Louguet C, Sgro C, Dalac S, Dutronc Y, Lambert D. Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist. Ann Dermatol Venereol. 2002;129:1033–6.

    CAS  PubMed  Google Scholar 

  23. Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.

    Google Scholar 

  24. Mutasim DF. Lymphomatoid drug eruption mimicking digitate dermatosis: cross reactivity between two drugs that suppress angiotensin II function. Am J Dermatopathol. 2003;25:331–4.

    Article  PubMed  Google Scholar 

  25. Sawada Y, Yoshiki R, Kawakami C, Fukamachi S, Sugita K, Nakamura M, Tokura Y. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol. 2010;90:521–2.

    Article  PubMed  Google Scholar 

  26. Gambini D, Sala F, Gianotti R, Cusini M. Exanthematous reaction to irbesartan. J Eur Acad Dermatol Venereol. 2003;17:472–3.

    Article  CAS  PubMed  Google Scholar 

  27. Viraben R, Lamant L, Brousset P. Losartan-associated atypical cutaneous lymphoid hyperplasia. Lancet. 1997;350:1366.

    Article  CAS  PubMed  Google Scholar 

  28. Bosch X. Henoch-Schonlein purpura induced by losartan therapy. Arch Intern Med. 1998;158:191–2.

    Article  CAS  PubMed  Google Scholar 

  29. Brouard M, Piguet V, Chavaz P, Borradori L. Schonlein-Henoch purpura associated with losartan treatment and presence of antineutrophil cytoplasmic antibodies of x specificity. Br J Dermatol. 2001;145:362–3.

    Article  CAS  PubMed  Google Scholar 

  30. Morton A, Muir J, Lim D. Rash and acute nephritic syndrome due to candesartan. BMJ. 2004;328:25.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Piérard Franchimont C, Henry F, Piérard GE. Severe pustular and polymorphous vasculitis caused by losartan. Ann Dermatol Venereol. 2001;128(10 Pt 1):1040–2.

    PubMed  Google Scholar 

  32. Pena-Penabad C, Rodriguez-Lozano J, del Pozo J, Garcia-Silva J, Fonseca E. Linear IgA bullous dermatosis induced by angiotensin receptor antagonists. Am J Med. 2003;114:163–4.

    Article  PubMed  Google Scholar 

  33. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33:154–5.

    Article  CAS  PubMed  Google Scholar 

  34. Femiano F. Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case. Minerva Stomatol. 2003;52:187–90.

    CAS  PubMed  Google Scholar 

  35. Bae YI, Yun SJ, Lee SC, Park GT, Lee JB. Pemphigus foliaceus induced by an angiotensin II receptor blocker. Clin Exp Dermatol. 2008;33:721–3.

    Article  CAS  PubMed  Google Scholar 

  36. Gencoglan G, Ceylan C, Kazandi AC. Linear lichenoid drug eruption induced by valsartan. Clin Exp Dermatol. 2009;34:e334–5.

    Article  CAS  PubMed  Google Scholar 

  37. Pfab F, Athanasiadis GI, Kollmar A, Ring J, Ollert M. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide. Allergy. 2006;61:786–7.

    Article  CAS  PubMed  Google Scholar 

  38. Ozturk G, Turk BG, Senturk B, Turkmen M, Kandiloglu G. Exanthematous drug eruption due to valsartan. Cutan Ocul Toxicol. 2012;31:335–7.

    Article  CAS  PubMed  Google Scholar 

  39. Ejaz AA, Walsh JS, Wasiluk A. Erythema multiforme associated with candesartan cilexetil. South Med J. 2004;97:614–5.

    Article  PubMed  Google Scholar 

  40. Bonnici H, Bygum A. Losartan-induced Stevens-Johnson syndrome in a geriatric patient. Ugeskr Laeger. 2007;169:1233–4.

    PubMed  Google Scholar 

  41. Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis. 2010;16:769–73.

    Article  CAS  PubMed  Google Scholar 

  42. Chen C, Chevrot D, Contamin C, Romanet T, Allenet B, Mallaret M. Stomatitis and ageusia induced by candesartan. Nephrologie. 2004;25:97–9.

    CAS  PubMed  Google Scholar 

  43. Goffin E, Pochet JM, Lejuste P, De Plaen JF. Aphthous ulcers of the mouth associated with losartan. Clin Nephrol. 1998;50:197.

    CAS  PubMed  Google Scholar 

  44. Castells X, Rodoreda I, Pedrós C, Cereza G, Laporte JR. Drug points: dysgeusia and burning mouth syndrome by eprosartan. BMJ. 2002;325:1277.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Heeringa M, van Puijenbroek EP. Reversible dysgeusia attributed to losartan. Ann Intern Med. 1998;129:72.

    Article  CAS  PubMed  Google Scholar 

  46. Schlienger RG, Saxer M, Haefeli WE. Reversible ageusia associated with losartan. Lancet. 1996;347:471–2.

    Article  CAS  PubMed  Google Scholar 

  47. Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part II. Cardiol Rev. 2002;10:285–300.

    Article  PubMed  Google Scholar 

  48. Ferreira O, Mota A, Morais P, Cunha AP, Azevedo F. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartan-hydrochlorothiazide. Cutan Ocul Toxicol. 2010;29:293–5.

    Article  PubMed  Google Scholar 

  49. Packard KA, Arouni AJ, Hilleman DE, Gannon JM. Fingernail clubbing and chromonychia associated with the use of angiotensin II receptor blockers. Pharmacotherapy. 2004;24:546–50.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Esen Özkaya & Kurtuluş Didem Yazganoğlu

Authors
  1. Esen Özkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurtuluş Didem Yazganoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Özkaya, E., Yazganoğlu, K.D. (2014). Angiotensin II Receptor Blockers. In: Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-6536-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6536-1_3

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6535-4

  • Online ISBN: 978-1-4471-6536-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation